Halliburton Co
Change company Symbol lookup
Select an option...
HAL Halliburton Co
DPZ Domino's Pizza Inc
CLOEF Cloetta AB
CHH Choice Hotels International Inc
PRAC Productivity Technologies Corp
BAC Bank of America Corp
USAK USA Truck Inc
BABA Alibaba Group Holding Ltd
CTL Centurylink Inc

Energy : Energy Equipment & Services | Mid Cap Value
Company profile

Halliburton Company provides services and products to the upstream oil and natural gas industry throughout the lifecycle of the reservoir, from locating hydrocarbons and managing geological data, to drilling and formation evaluation, well construction and completion, and optimizing production throughout the life of the field. It operates through two segments: the Completion and Production segment, and the Drilling and Evaluation segment. The Completion and Production segment delivers cementing, stimulation, intervention, pressure control, specialty chemicals, artificial lift and completion services. The Drilling and Evaluation segment provides field and reservoir modeling, drilling, evaluation and wellbore placement solutions that enable customers to model, measure, drill and optimize their well construction activities. It serves national and independent oil and natural gas companies. As of December 31, 2016, it had conducted business in approximately 70 countries around the world.

Closing Price
Day's Change
-0.19 (-0.79%)
B/A Size
Day's High
Day's Low
(Heavy Day)

10-day average volume:

Aslan Pharmaceuticals stock plunges after stock offering prices at a 52% discount

2:29 pm ET December 3, 2019 (MarketWatch)

The U.S.-listed shares of Aslan Pharmaceuticals Ltd. (6497.OT) plunged 47% in active afternoon trading on Tuesday, after the Singapore-based biotechnology company's stock offering priced at less than half the previous session's closing price. Trading volume was 7.4 million shares, compared with the full-day average of about 2.1 million shares. The company announced in midday trading Monday that it had commenced a public offering of American Despositary Shares (http://ir.aslanpharma.com/news-releases/news-release-details/aslan-pharmaceuticals-announces-proposed-public-offering), but did not disclose the number of ADS to be sold or estimate a price. The stock closed Monday at $5.20, a 14-fold rise from the Nov. 13 record closing low of 37 cents, amid upbeat data from studies of its ASLAN004 and ASLAN003 products (http://www.marketwatch.com/story/aslan-pharmaceuticals-stock-soars-on-heavy-volume-after-rocketing-nearly-9-fold-the-past-week-2019-12-02). Late Monday, the company said its public offering of about 5.1 million ADS priced at $2.50 per ADS, or 52% below Monday's closing price, for expected proceeds of about $12.8 million. All of the ADS in the offering were sold by the company. The stock has run up 71% over the past three months, but was still down 23% year to date. In comparison, the iShares Nasdaq Biotechnology ETF (IBB) has run up 23% this year and the S&P 500 has climbed 23%.

-Tomi Kilgore; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

December 03, 2019 14:29 ET (19:29 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.